Technical Analysis for LABP - Landos Biopharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 22.93 | 0.58% | 0.13 |
LABP closed up 0.58 percent on Thursday, May 23, 2024, on 1.81 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Ulcerative Colitis Gastroenterology Abdominal Pain Colitis Crohn's Disease Diabetic Nephropathy Diarrhea
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Ulcerative Colitis Gastroenterology Abdominal Pain Colitis Crohn's Disease Diabetic Nephropathy Diarrhea
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.94 |
| 52 Week Low | 2.5 |
| Average Volume | 28,098 |
| 200-Day Moving Average | 8.25 |
| 50-Day Moving Average | 19.89 |
| 20-Day Moving Average | 22.35 |
| 10-Day Moving Average | 22.43 |
| Average True Range | 0.32 |
| RSI (14) | 77.17 |
| ADX | 71.72 |
| +DI | 40.21 |
| -DI | 7.20 |
| Chandelier Exit (Long, 3 ATRs) | 21.98 |
| Chandelier Exit (Short, 3 ATRs) | 22.87 |
| Upper Bollinger Bands | 22.74 |
| Lower Bollinger Band | 21.97 |
| Percent B (%b) | 1.25 |
| BandWidth | 3.47 |
| MACD Line | 0.73 |
| MACD Signal Line | 0.93 |
| MACD Histogram | -0.2003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.22 | ||||
| Resistance 3 (R3) | 23.19 | 23.06 | 23.17 | ||
| Resistance 2 (R2) | 23.06 | 22.99 | 23.08 | 23.15 | |
| Resistance 1 (R1) | 23.00 | 22.95 | 23.03 | 23.03 | 23.14 |
| Pivot Point | 22.87 | 22.87 | 22.89 | 22.89 | 22.87 |
| Support 1 (S1) | 22.81 | 22.80 | 22.84 | 22.84 | 22.72 |
| Support 2 (S2) | 22.68 | 22.76 | 22.70 | 22.71 | |
| Support 3 (S3) | 22.62 | 22.68 | 22.69 | ||
| Support 4 (S4) | 22.65 |
